Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Clin Pharmacol Ther. 2008 Jul 9;84(6):715–721. doi: 10.1038/clpt.2008.139

Figure 3.

Figure 3

Primary and secondary outcomes by ADRB2 Gly16-Glu27-523C haplotype and antihypertensive drug therapy. *Crude incidence per 1,000 patient years. †Includes only patients ever exposed to atenolol (94% in atenolol strategy). ‡Hazard ratios based on reduced model adjusted for age, sex, and race/ ethnicity. MI, myocardial infarction; SR, sustained release.